Review Article, Int J Ophthalmic Pathol Vol: 7 Issue: 1
Three-year Outcomes of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Wet ARMD at the Western Eye Hospital
Hamoud A1, Almeida G1, Kurumthottical M2, Goodluck A3, Yang E3, Pasu R4, Quijano C3 and Younis S3
1Department of Ophthalmology Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust UK, United Kingdom
2Ophthalmology Department, Queen Elizabeth Hospital Birmingham UK, United Kingdom
3Medical Retina Department, Western Eye Hospital- Imperial College Healthcare NHS Trust UK, United Kingdom
4Moorfields Eye Hospital NHS Foundation Trust UK, United Kingdom
*Corresponding Author : Hamoud Aseel
FRCS Glasg, Department of Ophthalmology Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust UK, United Kingdom
Tel: 447470185991
E-mail: aseelhamoud@yahoo.com
Received: February 01, 2018 Accepted: March 14, 2018 Published: March 21, 2018
Citation: Hamoud A, Almeida G, Kurumthottical M, Goodluck A, Yang E, et al. (2018) Three-year Outcomes of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Wet ARMD at the Western Eye Hospital. Int J Ophthalmic Pathol 7:1.doi: 10.4172/2324-8599.1000215
Abstract
Wet age-related macular degeneration wARMD is the leading cause of central visual loss in elderly patients in the developed countries. Overexpression of vascular endothelial grown factor (VEGF) is known to play a major role in the pathogenesis of choroidal neovascularization. Aflibercept is a fully human, recombinant fusion protein that inhibits VEGF. It has a higher tendency to combine with VEGF-A and it blocks other factors such as VEGF-B and placental growth.
